Mapping the Spread of Malaria Drug Resistance by Anderson, Tim
Perspective
Mapping the Spread of Malaria Drug Resistance
Tim Anderson*
Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas, United States of America
Drug resistance is a recurrent theme in
the history of infectious disease control. In
the case of malaria, resistance to all but one
o ft h ef i v em a j o rc l a s s e so fd r u g si s
widespread [1]. Such resistance occurs
because of the strong selection pressure
associated with giving patients antimalarial
drugs.
The most effective way to stall resis-
tance would therefore be to eliminate
selection by halting drug treatment [2],
but this is rarely a feasible option. Hence
alternative approaches to managing resis-
tance are needed. First of all, we need to
better understand the manner in which
resistance evolves and spreads within
populations.
Molecular methods provide the tools
needed for investigating the evolution and
the spread of resistance genes. These
methods can be used to answer a multi-
tude of pertinent questions: Do resistance
alleles have few or many origins? Do they
spread locally or globally? Do parasites
form a single pan-African population, or
are there barriers to gene flow? In turn,
the answers to these questions can be used
to make rational decisions about drug
treatment policy.
Sulfadoxine Resistance
Sulfadoxine (SDX) forms one half of the
drug combination sulfadoxine-pyrimeth-
amine (Fansidar), which replaced chloro-
quine as the first-line drug in much of
Africa, before itself being replaced by
artemisinin combination therapies. Resis-
tance to both SDX and pyrimethamine
(PYR) has spread rapidly within Africa.
Because the genetic basis of resistance to
these drugs is well established—single
point mutations within the enzyme active
sites [3]—SDX and PYR treatment pro-
vide excellent opportunities for under-
standing resistance evolution.
In a new study in PLoS Medicine, Cally
Roper and colleagues describe molecular
variation in alleles at the dihydropteroate
synthase (dhps) locus, which is known to
underlie resistance to SDX, in over 5,000
parasites from 50 locations during 2000–
2007 [4]. They also examine sequence
variation flanking this locus to determine
the number of independent origins of
resistance alleles. This unusually large data
set provides an extraordinarily fine-
grained view of the spread of resistance
alleles across Africa.
Curious Distribution of
Resistance Alleles in East and
West Africa
The maps generated by Roper and
colleagues show a striking distribution of
dhps alleles in Africa. Parasites bearing
amino acids SGE (underlining denotes
amino acids conferring resistance) at
codons 436, 437, and 540 in dhps are
common in east Africa, while parasites
bearing AGK and SGK alleles are com-
mon in west Africa. The demonstration
(below) that each one of these alleles has
multiple origins suggests the action of
selection. However, there are no obvious
differences in treatment or biology of
malaria in east and west Africa that
explain repeated origins of dissimilar
alleles. An alternative explanation is that
the same alleles have arisen on multiple
occasions because they were present
within parasite populations at low levels
prior to initiation of SDX-PYR selection.
How Many Times Have
Resistance Alleles Arisen?
The data from flanking microsatellite
markers reveal that there have been a
minimum of five independent origins of
resistance, which show strong geographi-
cal clustering. SGE alleles have arisen at
least twice in the east, with one lineage in
Ethiopia and Sudan and the other span-
ning from Kenya to South Africa. In west
Africa, there are three lineages of alleles; in
each lineage both AGK and SGK are
found on a common background, suggest-
ing that one has given rise to the other.
Once again, the three AGK/SGK lineag-
es have a strikingly focal distribution;
lineage 1 is found from Namibia to
Gabon, lineage 2 in Cameroon, and
lineage 3 from Nigeria to Senegal.
How can we explain this focal distribu-
tion of allelic lineages? One possibility is
that resistance alleles have spread like
ripples on a pond from a limited number
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Pearce RJ, Pota H, Evehe M-SB, Ba ˆ E-
H, Mombo-Ngoma G, et al. (2009)
Multiple origins and regional dis-
persal of resistant dhps in African
Plasmodium falciparum malaria.
PLoS Med 6(4): e1000055. doi:
10.1371/journal.pmed.1000055
Cally Roper and colleagues analyze
the distribution of sulfadoxine re-
sistance mutations and flanking
microsatellite loci to trace the
emergence and dispersal of drug-
resistant Plasmodium falciparum
malaria in Africa.
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between parasites bearing different resis-
tance allele lineages merely reflect meeting
points between ripples, and these bound-
aries are expected to become blurred and
disappear over time. Alternatively, the
distinctive focal distribution could result
from barriers to mixing and gene flow
between parasite subpopulations.
How can the opposing ‘‘ripples on a
pond’’ and ‘‘barriers to mixing’’ models be
distinguished? One option might be to
examine patterns of spread of resistance
genes to other antimalarial drugs. If
similar distribution patterns are observed
at different resistance loci, then this may
be indicative of common boundaries to
gene flow. It will be extremely interesting
to see if a pan-African analysis of dihy-
drofolate reductase (dhfr), which confers
resistance to PYR, shows similar patterns.
Furthermore, if boundaries between allelic
lineages correspond to physical barriers
such as mountain ranges or linguistic
barriers between human populations, this
further bolsters the ‘‘barriers to mixing’’
model.
Inferring the presence of barriers be-
tween populations using genes that are
known to be under strong selection is
fraught with problems [5]. Perhaps a more
convincing approach might be to use the
thousands of single nucleotide polymor-
phisms (SNPs) discovered by parasite re-
sequencing projects [6] to infer parasite
population structure. These can be scored
using microarrays or short-read sequenc-
ing (Solexa), and the majority will not be
influenced by selection. The power afford-
ed by use of thousands of markers may
reveal discontinuities in parasite popula-
tions that were not evident in smaller
previous studies [7].
Implications for Resistance
Surveillance and Malaria
Control
This new study provides a number of
important lessons. First, it illustrates the
practicality of routine measurement of
drug resistance allele frequencies across
malaria-endemic regions. Such measure-
ment allows policy makers direct access to
information required to make national
drug policy decisions. This new study
was done in a single laboratory, using
samples from multiple countries, showing
that centralization can provide a practical
way to generate such databases. The
alternative model—multiple regional lab-
oratories generating such data—will be
more expensive and less practical from a
control quality standpoint. Notably, this
work was done with quite simple molec-
ular methods—hybridization on nylon
membranes. Rapid SNP typing approach-
es now allow multiple resistance SNPs to
be genotyped in a single assay at low cost
[8], which can further streamline geo-
graphical mapping of multiple resistance
determinants.
The distinctive differences observed
between east and west Africa have clear
clinical implications. The dhps alleles with
two mutations (SGE) confer higher levels
of resistance than those carrying single
mutations (AGK and SGK) [9], suggesting
that SDX-PYR treatment will be less
effective in east than west Africa. Hence
interventions that use SDX-PYR, such as
intermittent preventative therapy for in-
fants or pregnant women, might be
expected to differ in efficacy depending
on location.
Given that just one or two SNPs are
required for resistance, and infected peo-
ple may contain more than 10
11 parasites
[10], the finding that resistance alleles
have only five origins is surprising, but
consistent with limited numbers of origins
observed at other drug resistance loci in
malaria parasites [11] and some popula-
tion genetic models [12]. This observation
bodes well for current control efforts using
artemisinin combination therapies. If re-
sistance has relatively few independent
origins, then simple strategies like combi-
nation therapy may be extremely effective
in stalling resistance evolution [10,13]. On
the other hand, if resistance arises com-
monly, then such measures are more likely
to be ineffective.
Finally, Roper and colleagues’ study
generates a testable hypothesis that malar-
ia parasite populations in Africa are
divided into regional subpopulations sep-
arated by barriers to gene flow. Further
data are required to substantiate this
hypothesis. If true, this hypothesis has
important implications as it suggests that
malaria control needs to be tailored to
regional parasite subpopulations rather
than to the continent as a whole.
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